Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine Race: Moderna or Vaxart?

By Adria Cimino – Jul 9, 2020 at 10:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both companies are developing new types of vaccines. The risk is high -- but so is potential for share performance.

Let's talk about two companies developing COVID-19 vaccines that are much different from the ones we're generally used to. These two aren't going the traditional route of injecting a weakened version of the pathogen into the body. They have new ways of addressing the problem.

You've probably heard of Moderna (MRNA -3.19%) by now. Moderna has taken center stage over the past few months as it became the first company to bring a COVID-19 vaccine into human trials. The biotech company is developing a vaccine that harnesses the power of messenger RNA to instruct the body to make proteins to defend itself.

A woman holds a glass of water and shows two pills in her other hand.

Image source: Getty Images.

Vaxart (VXRT 3.59%) has emerged as another player with interesting technology. The company is working on an oral vaccine -- a pill -- that does its work in the small bowel. Vaxart recently said that Operation Warp Speed, the government's effort to help bring a COVID-19 vaccine to market, had selected its vaccine to participate in a non-human primate challenge study.

Two innovative companies

Which of these two innovative companies offers investors the best coronavirus buy right now? Here's a closer look.

Moderna and Vaxart are both clinical-stage companies, meaning they don't have commercialized products. Moderna's pipeline is larger and more advanced, with about 20 candidates in preclinical to phase 2 development. Besides COVID-19, Moderna's pipeline includes vaccines for other infectious diseases, cancer, and autoimmune disorders.

As for Vaxart, its pipeline includes four other candidates in preclinical to phase 1 for influenza, norovirus, respiratory syncytial virus (a cold-like virus), and human papillomavirus.

At the moment, the share price of both companies is all about what happens in the COVID-19 vaccine program.

Moderna stands several steps ahead of Vaxart when it comes to timeline. Moderna's vaccine entered a phase 1 clinical trial in March, and the company already has reported positive interim data from the study and started a phase 2 trial. Phase 3 will begin this month.

Easy road ahead -- or not?

Though this seems like smooth sailing, risks remain. Moderna's initial study involved younger participants only. Now, Moderna has begun testing on volunteers over age 55.

Success in older people is critical because COVID-19 has in many cases been deadly for the elderly. Moderna also has to show -- in all age groups -- that its vaccine can produce significant levels of neutralizing antibodies, the ones that block infection. The company so far only had neutralizing antibody data on eight patients.

Vaxart recently formed manufacturing partnerships to produce vaccine tablets for its first human trials, which it hopes to begin as early as this summer. In the meantime, the Operation Warp Speed study in non-human primates might offer clues about the vaccine's potential -- and open the door for government funding.

Though Vaxart reported encouraging preclinical results, with all tested animals showing immune response after one dose, it's too early to judge whether the technology will work in humans. The positive thing we do know about Vaxart's candidate right now has to do with logistics. Vaxart is working with two manufacturers for bulk production of a vaccine, but the tablet itself will be manufactured by Vaxart itself.

The company doesn't need the "fill finish" process (involving the filling and packaging of doses) used by injectable vaccines. Without fill finish, Vaxart avoids possible delays at busy manufacturing sites. And the other plus is that the Vaxart vaccine is room-temperature stable, meaning it's easy to store and transport to healthcare facilities.

The financial picture

As for the financial picture, Vaxart had nearly $30 million in cash as of March 31. Moderna has $2.4 billion to invest, the company said in its first-quarter earnings report. Vaxart, with shares that have increased 25-fold so far this year, has a market value of $842 million. Moderna shares have climbed 212%, giving the company a market capitalization of almost $23 billion.

Which biotech stock is the better one to choose? Without products on the market or proof that their technologies truly work in humans, both companies remain risky business for investors. But if I wanted to make a small investment outside my usual comfort level for risk, I would go with Moderna. So far, financials, study data, and timeline indicate the company may be more likely to win the coronavirus vaccine race.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$119.69 (-3.19%) $-3.95
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$2.17 (3.59%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.